Profile data is unavailable for this security.
About the company
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.
- Revenue in USD (TTM)0.00
- Net income in USD-7.85m
- Incorporated2017
- Employees2.00
- LocationHoth Therapeutics Inc590 Madison Avenue, 21St FloorNEW YORK 10022United StatesUSA
- Phone+1 (646) 756-2997
- Websitehttps://hoththerapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Integrated BioPharma, Inc. | 50.52m | -385.00k | 5.75m | 141.00 | -- | 0.3095 | -- | 0.1137 | -0.0128 | -0.0128 | 1.68 | 0.6168 | 1.95 | 4.21 | 12.26 | 358,269.50 | -1.49 | 15.51 | -1.89 | 27.94 | 6.62 | 12.09 | -0.7621 | 6.44 | 0.8428 | -22.53 | 0.0015 | -- | -9.91 | 3.00 | -101.35 | -- | -14.03 | -- |
| Soligenix Inc | 839.36k | -6.14m | 5.76m | 13.00 | -- | 1.66 | -- | 6.86 | -0.9164 | -0.9164 | 0.1085 | 0.243 | 0.0697 | -- | 5.86 | 64,566.15 | -51.01 | -75.40 | -872.23 | -154.32 | 11.59 | 22.83 | -731.60 | -620.02 | -- | -1,677.11 | 0.5639 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| Goldenwell Biotech Inc | 2.34k | -116.90k | 5.80m | -- | -- | 68.48 | -- | 2,479.23 | -0.0012 | -0.0012 | 0.00002 | 0.0009 | 0.0098 | 0.0071 | -- | -- | -49.07 | -- | -52.16 | -- | 47.01 | -- | -4,995.73 | -- | 37.75 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -415.48k | 5.85m | 0.00 | -- | 13.41 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0013 | 0.00 | -- | -- | -- | -88.08 | -696.88 | -96.94 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| Sonnet Biotherapeutics Holdings Inc | 129.19k | -14.46m | 5.89m | 12.00 | -- | 2.29 | -- | 45.62 | -12.91 | -12.91 | 0.0676 | 0.8381 | 0.0251 | -- | 0.1688 | 10,765.83 | -281.29 | -- | -- | -- | -- | -- | -11,192.09 | -- | -- | -- | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| Healthy Extracts Inc | 2.49m | -2.47m | 5.93m | -- | -- | 6.19 | -- | 2.38 | -0.8588 | -0.8588 | 0.8611 | 0.3231 | 0.918 | 0.4921 | 36.50 | -- | -91.32 | -53.78 | -174.02 | -146.65 | 65.90 | 45.68 | -99.48 | -87.53 | 0.1636 | -9.72 | 0.5245 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| Hoth Therapeutics Inc | 0.00 | -7.85m | 6.01m | 2.00 | -- | 0.6062 | -- | -- | -2.44 | -2.44 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -96.38 | -157.07 | -110.40 | -177.32 | -- | -- | -- | -- | -- | -50.23 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.54m | -4.13m | 6.01m | 4.00 | -- | 0.6135 | -- | 2.37 | -2.70 | -2.70 | 1.66 | 6.36 | 0.2006 | -- | -- | 634,995.00 | -32.65 | -48.91 | -35.27 | -52.82 | -- | -- | -162.78 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| Protagenic Therapeutics Inc | 0.00 | -5.00m | 6.10m | -- | -- | 1.66 | -- | -- | -1.15 | -1.15 | 0.00 | 0.8271 | 0.00 | -- | -- | -- | -80.91 | -74.49 | -94.48 | -92.56 | -- | -- | -- | -- | -- | -9.56 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
| Titan Pharmaceuticals Inc | 185.00k | -5.57m | 6.13m | 4.00 | -- | 0.7884 | -- | 33.11 | -7.40 | -7.40 | 0.246 | 8.50 | 0.0305 | -- | 4.51 | 46,250.00 | -91.72 | -96.80 | -138.02 | -156.65 | -- | -- | -3,010.27 | -406.26 | 5.55 | -- | 0.07 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Kintara Therapeutics Inc | 0.00 | -10.77m | 6.14m | 2.00 | -- | -- | -- | -- | -5.98 | -5.98 | 0.00 | -0.0157 | 0.00 | -- | -- | 0.00 | -179.36 | -220.94 | -316.27 | -329.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| Theralink Technologies Inc | 635.46k | -13.50m | 6.15m | 16.00 | -- | -- | -- | 9.68 | -0.0027 | -0.0027 | 0.00006 | -0.0093 | 0.2525 | -- | 13.51 | 39,716.25 | -536.39 | -- | -- | -- | 73.50 | -- | -2,124.10 | -- | -- | -1.35 | -- | -- | 6.85 | -- | -138.38 | -- | -- | -- |
| Creative Medical Technology Holdings Inc | 9.00k | -5.29m | 6.17m | 4.00 | -- | 0.6042 | -- | 685.85 | -3.76 | -3.76 | 0.0064 | 7.53 | 0.0006 | 0.4291 | -- | 2,250.00 | -35.36 | -110.00 | -40.34 | -- | 60.00 | 65.82 | -58,739.67 | -7,961.14 | 27.64 | -- | 0.00 | -- | -89.84 | -40.86 | 47.88 | -- | -- | -- |
| Ainos Inc | 122.11k | -13.77m | 6.19m | 46.00 | -- | 0.199 | -- | 50.71 | -3.32 | -3.32 | 0.0298 | 5.23 | 0.0035 | 0.9854 | 1.21 | 2,654.57 | -39.94 | -36.36 | -42.28 | -58.33 | -207.80 | 36.82 | -11,277.18 | -813.63 | 1.72 | -91.59 | 0.1961 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
| Palisade Bio Inc | 250.00k | -12.30m | 6.21m | 9.00 | -- | 0.3984 | -- | 24.83 | -28.22 | -28.22 | 0.5485 | 18.30 | 0.0168 | -- | 0.3153 | 27,777.78 | -82.51 | -132.36 | -101.58 | -165.45 | -- | -- | -4,920.00 | -27,892.32 | -- | -856.33 | 0.0138 | -- | -- | -0.7814 | 13.74 | -- | 18.53 | -- |
| TFF Pharmaceuticals Inc | 733.87k | -21.24m | 6.22m | 19.00 | -- | 0.6119 | -- | 8.48 | -12.67 | -12.67 | 0.4097 | 4.04 | 0.0406 | -- | 2.37 | 38,624.74 | -117.54 | -79.57 | -130.37 | -83.41 | -- | -- | -2,894.69 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Hoth Therapeutics Inc's reporting currency: US Dollar USD
1.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 38.80k | 0.89% |
| Geode Capital Management LLCas of 31 Dec 2023 | 23.50k | 0.54% |
| UBS Securities LLCas of 31 Dec 2023 | 6.30k | 0.15% |
| JPMorgan Securities LLC (Investment Management)as of 31 Dec 2023 | 4.98k | 0.11% |
| UBS Financial Services, Inc.as of 31 Dec 2023 | 2.15k | 0.05% |
| Tower Research Capital LLCas of 31 Dec 2023 | 1.56k | 0.04% |
| JPMorgan Asset Management (Europe) SARL (Germany)as of 31 Dec 2023 | 1.36k | 0.03% |
| Brewin Dolphin Wealth Management Ltd.as of 31 Dec 2023 | 240.00 | 0.01% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Dec 2023 | 30.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 6.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
